In CKD patients, pioglitazone treatment led also to significantly increased plasma adiponectin levels together with decreased glucose levels (Zanchi et al., 2014) as we see in our model as well, indicative for successful PPARγ activation by pioglitazone. The gene discussed is ADIPOQ; the disease is chronic kidney disease.